Neglected Tropical Diseases Diagnosis Market Size & Forecast
The global neglected tropical diseases diagnosis market was valued at USD 7.42 billion in 2025 and is projected to reach USD 11.30 billion by 2035, growing at a CAGR of 4.3% during 2026–2035. The market includes instruments, reagents, rapid tests, laboratory assays and diagnostic services used to identify, confirm, monitor or support surveillance of diseases classified within the neglected tropical disease portfolio. The scope covers dengue, Chagas disease, leishmaniasis, schistosomiasis, lymphatic filariasis, onchocerciasis, trachoma, human African trypanosomiasis, leprosy, mycetoma and other recognized NTDs.
The commercial structure differs from conventional infectious-disease diagnostics. High disease burden is concentrated in low- and middle-income countries, while a large share of purchasing depends on ministries of health, multilateral programmes, donor-funded procurement and outbreak budgets. Revenue is therefore shaped by funding cycles, national elimination targets, test-list inclusion, product registration, field durability and evidence that a test can work outside a fully equipped laboratory.
The World Health Organization reported that 1.495 billion people required interventions against NTDs in 2023 and 867.1 million received treatment for at least one NTD. WHO also facilitated procurement of more than one million diagnostic tests for five NTDs in 2024. These figures demonstrate the scale of public-health operations, but they do not translate directly into private-market revenue. Tests must be inexpensive, deployable and connected to a treatment or surveillance decision to receive sustained programme funding.
The market is moving in two directions. Decentralized rapid tests are expanding access at community, pharmacy and primary-care levels, while automated immunoassay and molecular platforms are improving confirmation, throughput and surveillance in reference laboratories. The strongest product strategies link both tiers: a low-complexity screen near the patient, followed by a more specific confirmatory method and digital reporting.
Key Highlights
- Market revenue is forecast to increase from USD 7.42 billion in 2025 to USD 11.30 billion in 2035 at a 4.3% CAGR, supported by dengue expansion, elimination surveillance and wider access to point-of-care testing.
- Dengue diagnostics represented 39% of 2025 revenue, reflecting record case activity, frequent testing during acute febrile illness and use across both endemic and travel-related settings.
- Rapid diagnostic tests held 37% of the market, while molecular diagnostics generated 26%. Rapid tests lead in volume, but molecular platforms capture higher revenue per confirmed result.
- Hospitals and diagnostic laboratories accounted for 61% of 2025 revenue. Community programmes and primary-care settings are growing faster as health systems decentralize fever and skin-disease assessment.
- North America held 32% of global revenue because of high test prices, reference-laboratory capacity, travel medicine and major diagnostic suppliers, despite carrying a smaller share of endemic disease burden.
- Asia-Pacific represented 30% and is projected to grow fastest through 2035, led by dengue testing, national elimination programmes, urban laboratory expansion and local kit manufacturing.
- Procurement qualification is becoming more important than catalogue breadth. WHO review, national registration, independent performance evidence, shelf life and heat stability determine whether a test reaches funded campaigns.
Diagnostic Need Is Shifting from Case Detection to Elimination Evidence
NTD programmes historically prioritized finding symptomatic patients and supporting mass drug administration. As countries reduce transmission, the diagnostic requirement changes. Low-prevalence settings need more sensitive tools, stronger specificity and reliable confirmation because false positives can trigger unnecessary intervention, while missed infections can allow transmission to continue.
Schistosomiasis illustrates this transition. Conventional egg detection is useful but can miss low-intensity infections and requires trained staff. WHO target product profiles call for field-suitable tools that help programmes decide whether prevalence remains above treatment thresholds and whether transmission has been interrupted. Similar requirements apply to lymphatic filariasis, onchocerciasis and visceral leishmaniasis. Demand therefore moves from episodic testing toward structured mapping, monitoring, verification and post-elimination surveillance.
This shift favors products with lot consistency, external quality controls and digital traceability. A test that performs well in a research laboratory may still fail procurement if it requires cold storage, complex sample preparation or repeat visits to remote communities. Market access depends on the full operating model, not analytical performance alone.
Market Dynamics
Dengue Expansion Is Broadening the Addressable Testing Base
Dengue is the largest commercial component of NTD diagnostics. The disease now affects more than 100 countries, and outbreaks create sudden demand for high-volume screening and laboratory confirmation. Clinical symptoms overlap with chikungunya, Zika, malaria and other causes of acute fever, which increases the value of differential diagnosis. Testing demand also varies by disease stage: NS1 antigen and nucleic-acid methods are most useful early, while IgM and IgG support later-stage or exposure assessment.
In April 2025, Abbott launched its Bioline Dengue Duo fingerstick test in Brazil after authorization for pharmacy and clinic use. The assay detects NS1 antigen and IgG/IgM antibodies and returns results in 15–20 minutes. In October 2025, Roche received CE marking for the automated Elecsys Dengue Ag assay, which runs on cobas e analyzers and delivers results in 18 minutes. These launches show two distinct commercial paths: decentralized testing close to the patient and centralized high-throughput processing during outbreaks.
Elimination Programmes Create Recurring Surveillance Demand
Disease elimination does not remove the need for diagnostics. It raises the standard required for surveillance. Countries must demonstrate interruption of transmission, investigate suspected cases, monitor animal or vector reservoirs and sustain post-elimination checks. The World Health Assembly’s 2025 resolution on Guinea-worm eradication emphasized human, animal and environmental surveillance with laboratory confirmation. A separate resolution recognized skin diseases as a public-health priority and called for stronger laboratory capacity and integrated service delivery.
These policies support cross-disease platforms rather than isolated disease programmes. Health workers evaluating skin lesions may need to distinguish leprosy, cutaneous leishmaniasis, yaws, mycetoma and other conditions. Integrated algorithms can improve equipment utilization and reduce training costs, but they require clear referral and confirmation rules.
Point-of-Care Products Must Survive Real Field Conditions
Many target communities have limited electricity, refrigeration, transport and laboratory personnel. Successful tests need long shelf life, simple specimen collection, visual or low-cost reader interpretation and stable performance under heat and humidity. Fingerstick blood, urine and non-invasive samples can reduce collection barriers. Battery-powered readers and offline data capture improve deployment where connectivity is intermittent.
Low unit price is necessary but insufficient. Programme managers calculate the cost of training, invalid results, confirmatory testing, waste, distribution and supervision. Products with slightly higher acquisition prices can win if they reduce repeat visits or produce a same-day treatment decision. Packaging configuration also matters: large kit sizes create waste in low-volume rural facilities, while individually packed tests can cost more to manufacture and distribute.
Funding Volatility Limits Conversion of Disease Burden into Revenue
WHO reported that official development assistance for NTD programmes fell 41% between 2018 and 2023. This exposes the market’s central constraint: clinical need is extensive, but budgets are not. Donor reductions can delay tenders, reduce survey frequency and shift purchasing toward the lowest-cost products. National governments increasingly need to integrate NTD diagnostics into domestic health budgets, laboratory networks and universal-health-coverage packages.
Manufacturers face low and irregular volumes for several rare NTDs. Without pooled procurement or advance demand visibility, maintaining production can be commercially difficult. This creates a risk that technically useful products disappear because sales cannot support registration, quality systems and manufacturing continuity.
Test Performance Varies with Disease Stage and Geography
Antibody tests may remain positive after infection or cure, limiting their use for active-disease confirmation. Antigen tests can be more specific to current infection but may lose sensitivity at low parasite loads. Molecular assays offer high analytical performance, yet sample preparation and contamination control can restrict field use. Microscopy remains valuable and inexpensive in skilled hands but is labor-intensive and operator-dependent.
Geographic strain diversity, co-infections and prior exposure can also affect performance. Procurement agencies increasingly require evaluations in intended-use populations rather than relying only on manufacturer studies. Products must define whether they are designed for screening, confirmation, treatment monitoring or surveillance; ambiguous claims create clinical and procurement risk.
Strategic Takeaways
- Product development should begin with a defined programme decision-screen, confirm, treat, map or verify elimination-because a single assay rarely performs every role effectively.
- Dengue offers the largest scalable commercial opportunity, but competition is intensifying across rapid, automated immunoassay and molecular platforms; differentiation must focus on workflow and disease-stage coverage.
- WHO review, national registration and independent field evidence can determine tender access, making regulatory and evidence strategy as important as distributor coverage.
- Integrated fever and skin-disease testing can improve programme economics, provided confirmatory pathways and data reporting are built into the service model.
- Asia-Pacific suppliers can gain share through locally priced kits and manufacturing, while global companies retain advantages in automation, quality systems and installed laboratory platforms.
- Post-elimination surveillance creates durable demand even after incidence falls, but tests need higher specificity and sensitivity at low prevalence than tools used during mass-treatment phases.
- Funding volatility rewards manufacturers that offer demand forecasting, flexible pack sizes, training and supply continuity rather than depending on one-off product shipments.
Market Segmentation Analysis
By Disease
Dengue accounted for 39% of 2025 market revenue, making it the largest disease segment. Chagas disease represented 12%, supported by blood-donor screening, maternal testing and diagnostic confirmation across Latin America and non-endemic countries receiving migrants. Leishmaniasis held 11%, including rapid serology, microscopy and molecular confirmation for visceral and cutaneous forms. Schistosomiasis generated 9%, while lymphatic filariasis and onchocerciasis together represented 8%. Leprosy held 5%, human African trypanosomiasis 3%, trachoma 3%, and other NTDs collectively accounted for 10%.
Dengue is expected to retain the largest share through 2035 because climate suitability, urban transmission and outbreak frequency increase testing episodes. Surveillance-related demand for schistosomiasis, filariasis and onchocerciasis should grow steadily as countries approach elimination thresholds. Rare-disease segments may show uneven annual revenue because purchases are organized through campaigns rather than continuous routine testing.
By Diagnostic Method
Rapid diagnostic tests held 37% of 2025 revenue. Their leadership reflects low equipment needs, short turnaround and suitability for decentralized use. Molecular diagnostics accounted for 26%, led by PCR and multiplex nucleic-acid testing in reference laboratories. Immunoassays, excluding lateral-flow rapid tests, represented 20%, including ELISA and automated antigen or antibody assays. Microscopy and parasitology methods held 10%, while imaging, culture and other approaches represented 7%.
Molecular diagnostics are forecast to gain share where laboratories need differential fever panels, low-prevalence confirmation and genomic surveillance. Rapid tests will remain the volume leader because most endemic communities cannot rely on centralized equipment for every suspected case. Automated immunoassays will expand in high-throughput dengue settings with an existing analyzer base.
By Product and Service Type
Reagents, test kits and consumables generated 68% of 2025 revenue. Instruments and readers represented 17%, while diagnostic and laboratory services held 15%. Consumables dominate because outbreak testing and population surveys generate repeat demand. Instrument revenue is concentrated in molecular systems, immunoassay analyzers, microscopy and portable readers. Service revenue includes reference testing, confirmatory work, quality assessment and outsourced surveillance support.
By Sample Type
Blood, serum and plasma samples accounted for 72% of 2025 revenue because dengue, Chagas disease, leishmaniasis, filariasis and trypanosomiasis commonly use these matrices. Urine represented 10%, driven mainly by schistosomiasis and antigen-detection workflows. Stool accounted for 7%, tissue or lesion samples 6%, and ocular, saliva and other samples together held 5%. Non-invasive samples are gaining attention because they improve community acceptance, but the available biomarkers must meet programme sensitivity and specificity requirements.
By End User
Hospitals and clinical diagnostic laboratories represented 61% of 2025 revenue. Public-health and reference laboratories held 18%, community health programmes and mobile teams 11%, research institutes 6%, and blood banks and other users 4%. Hospital and laboratory dominance reflects higher-value molecular and automated testing. Community programmes use greater test volumes but face lower negotiated prices. Public-health laboratories are strategically important because they validate outbreaks, conduct surveillance and support national quality systems.
By Procurement Channel
Direct hospital and laboratory purchasing held 43% of 2025 revenue. Government and multilateral tenders accounted for 34%, distributors represented 18%, and retail pharmacies and other channels held 5%. Tender purchasing is most influential in endemic-country campaigns, where qualification standards, landed cost and delivery schedules determine awards. Retail diagnostics are expanding in selected dengue markets following regulatory authorization for pharmacy testing, but local rules vary widely.
Regional and Country-Level Analysis
North America
North America held 32% of global 2025 revenue, equal to USD 2.37 billion. The United States represented 27% of global sales, Canada 3% and Mexico 2%. Revenue leadership is driven by premium molecular and immunoassay pricing, travel and migrant testing, reference laboratories, blood-screening programmes and the headquarters or commercial operations of major diagnostic suppliers. The United States also supports NTD surveillance through federal public-health laboratories and specialist tropical-medicine centers.
The region’s revenue share is much higher than its endemic-disease burden. Mexico contributes direct dengue and Chagas testing demand, while the United States and Canada rely more heavily on imported-case diagnosis, blood safety, research and reference confirmation. Commercial access requires FDA or Health Canada pathways where applicable, laboratory validation and reimbursement clarity.
Asia-Pacific
Asia-Pacific accounted for 30% of 2025 revenue, or USD 2.23 billion, and is forecast to be the fastest-growing region. China held 8% of global revenue, India 7%, Japan 4%, Indonesia 3%, Thailand 2%, the Philippines 2%, Australia 2% and the rest of the region 2%. Dengue is the dominant demand generator, while leprosy, lymphatic filariasis, leishmaniasis, schistosomiasis and other diseases contribute country-specific needs.
India combines extensive programme demand with a growing local diagnostics industry, but procurement is highly price-sensitive and differs across national and state systems. China has substantial laboratory capacity and domestic manufacturing, supporting both surveillance and commercial testing. Japan and Australia generate higher revenue per test from travel medicine, imported infections and advanced laboratories. Indonesia, Thailand and the Philippines present strong rapid-test demand during dengue outbreaks, with distribution reach and heat stability shaping product performance in the market.
Europe
Europe generated 20% of global 2025 revenue, equal to USD 1.48 billion. Germany represented 4%, the United Kingdom 3.5%, France 3%, Italy 2.5%, Spain 2.5% and the rest of Europe 4.5%. Regional demand includes imported-case diagnosis, migrant health, blood safety, research and automated dengue or Chagas testing. Southern European countries also face changing vector conditions that increase surveillance needs.
Germany leads through its large laboratory market and installed molecular systems. The United Kingdom and France maintain tropical-disease reference expertise and public-health networks. Spain and Italy have stronger relevance for Chagas screening among migrant populations and heightened arbovirus surveillance. CE marking supports multi-country commercialization, but reimbursement, laboratory procurement and confirmatory algorithms remain nationally governed.
Recent Developments
- In January 2025, WHO prequalified a glucose-6-phosphate dehydrogenase diagnostic to support safer treatment decisions for Plasmodium vivax malaria. While malaria is managed through a separate WHO programme, the decision is relevant to tropical-disease diagnostics because it demonstrates how prequalification can connect a field test directly to safe medicine use and procurement.
- In April 2025, Abbott launched the Bioline Dengue Duo fingerstick rapid test in Brazil. The test detects NS1 antigen and IgG/IgM antibodies, can be used in pharmacies and clinics, and produces results within 15–20 minutes. Its decentralized authorization creates a commercial channel outside traditional laboratories.
- In May 2025, WHO activated an Expert Review Panel for dengue diagnostics in response to the 2024–2025 emergency. Seven products were listed following quality and performance review, supporting more informed procurement where conventional prequalification or stringent regulatory review was not available.
- In May 2025, the World Health Assembly adopted resolutions on Guinea-worm eradication and skin diseases as a public-health priority. Both measures reinforce laboratory confirmation, surveillance, integrated service delivery and diagnostic capacity at country level.
- In 2025, QIAGEN launched the QIAprep& Plasmodium Kit for malaria research and surveillance. The product supports standardized preparation for downstream molecular analysis and illustrates continued investment in surveillance-oriented workflows that can inform adjacent NTD laboratory infrastructure.
- In October 2025, Roche received CE marking for the Elecsys Dengue Ag assay. The automated test detects NS1 antigen across all four dengue serotypes, provides an 18-minute result and runs on cobas e 402 and e 801 analyzers, supporting medium- and high-throughput laboratories.
- The WHO Global Report on NTDs 2025 recorded procurement of more than one million diagnostic tests for five NTDs during 2024, while identifying diagnostics, monitoring, logistics and funding as continuing programme gaps. This combination supports demand but raises the evidence and supply requirements for manufacturers.
Competitive Landscape
The competitive field includes multinational platform companies, rapid-test specialists, molecular-diagnostics suppliers, quality-control providers and regional manufacturers. Large companies compete through installed instruments, automated workflows, regulatory teams and global distribution. Specialist companies compete through lower-cost field products, disease-specific expertise and access to public-health procurement.
No company dominates every NTD because disease biology, sample type and purchasing channel differ. Dengue attracts the broadest commercial competition. Chagas testing has strong blood-screening and migration-related demand. Schistosomiasis, filariasis and onchocerciasis rely more heavily on programme procurement and surveillance specifications. Companies that treat the market as a single product category risk misaligning price, evidence or distribution.
Partnerships with ministries, WHO, non-governmental organizations and reference laboratories are essential for field evaluation and demand planning. Competitive advantage increasingly includes training, connectivity, quality controls and dependable production through outbreak peaks.
Key Players
Abbott Laboratories; F. Hoffmann-La Roche Ltd.; bioMérieux SA; QIAGEN N.V.; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific Inc.; Danaher Corporation; Siemens Healthineers AG; Standard Diagnostics/SD Biosensor; DiaSorin S.p.A.; InBios International, Inc.; EUROIMMUN Medizinische Labordiagnostika AG; Fujirebio; Hologic, Inc.; Meridian Bioscience; and regional rapid-test manufacturers.
Abbott Laboratories
Abbott participates through rapid infectious-disease diagnostics designed for decentralized and laboratory settings. Its Bioline dengue portfolio includes antigen and antibody formats covering different stages of infection. The April 2025 Brazilian launch of the Bioline Dengue Duo fingerstick test extended testing into pharmacies and clinics, with a 15–20 minute result and coverage of NS1, IgG and IgM. Abbott’s advantage is a global rapid-diagnostics network and experience with high-volume infectious-disease supply. Its performance in NTD markets depends on national registrations, local channel execution and the ability to maintain affordable supply during outbreaks.
F. Hoffmann-La Roche Ltd.
Roche competes through automated laboratory systems with a large installed base. The CE-marked Elecsys Dengue Ag assay runs on cobas e analyzers, delivers a result in 18 minutes and is designed for high-throughput laboratories. Reported clinical performance included 94.90% sensitivity in PCR-confirmed samples and 99.96% relative specificity among healthy blood donors. Roche’s strategic advantage is laboratory automation, traceability and the ability to place dengue testing within an existing immunoassay workflow. The platform is best suited to urban and reference laboratories rather than remote field screening.
QIAGEN N.V.
QIAGEN supplies sample-preparation, PCR and syndromic molecular technologies used in infectious-disease research and surveillance. Its QIAprep& Plasmodium Kit, launched in 2025, was designed to strengthen malaria research and surveillance workflows. The company’s wider relevance to NTD diagnosis lies in standardized extraction and molecular testing for pathogens requiring sensitive confirmation. QIAGEN is positioned for reference laboratories, research programmes and surveillance networks. Cost, infrastructure and operator requirements restrict direct deployment at community level, making partnerships and tiered testing algorithms important.
Bio-Rad Laboratories, Inc.
Bio-Rad supports infectious-disease testing through immunoassays, laboratory instruments and quality controls. VIROTROL Chagas is a reactive human-serum control for assays that qualitatively detect antibodies to Trypanosoma cruzi. External quality materials are commercially important because public-health and blood-screening laboratories must verify assay performance over time. Bio-Rad’s strength is its established laboratory customer base and quality-control expertise. Its role is strongest in structured laboratories rather than mass community campaigns, where low-complexity rapid tests dominate volume.
